Vifor Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vifor Pharma sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Vifor Pharma: 12 sponsored US clinical trials, 1 recruiting.
Vifor Pharma sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. 4 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Drug Interaction Potentiation, with 1 trials.
Top-decile sponsor footprint
Vifor Pharma ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
12 total, page 1 of 1
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
NCT05766839
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
NCT03888066
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
NCT03087058
A Drug-Drug Interaction Study of Warfarin and PA21
NCT01477424
A Drug-Drug Interaction Study of Digoxin and PA21
NCT01477411
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
NCT01464190
A Drug-Drug Interaction Study of Omeprazole and PA21
NCT01452906
A Drug-Drug Interaction Study of Furosemide and PA21
NCT01438359
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
NCT01324128
A Drug-Drug Interaction Study of Losartan and PA21
NCT01324752
Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
NCT00994318
Study of Phosphate Levels in Patients With Chronic Kidney Disease
NCT00824460
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the Vifor Pharma pipeline
1 recruiting of 12 indexed (8% open); 10 completed (83%).
Phase mix: 4 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Drug Interaction Potentiation (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vifor Pharma: open-pipeline peers nationwide
Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Vifor Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Acrotech Biopharma · 8% recruiting · 24 trials
- Atlanta VA Medical Center · 8% recruiting · 12 trials
- Beacon Therapeutics · 8% recruiting · 12 trials
- Boston VA Research Institute · 8% recruiting · 12 trials
Related
What to do with this Vifor Pharma page
12 registered trials is a research-attention snapshot, not an endorsement of Vifor Pharma or any single study.
- 1 of Vifor Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Drug Interaction Potentiation is the condition Vifor Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Drug Interaction Potentiation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vifor Pharma pipeline card: 12 registered trials from official public datasets.Report a data error.